Molecular Partners AG, of Zurich, Switzerland, appointed Goran Ando to its board.

Myriad Genetics Inc., of Salt Lake City, elected Heiner Dreismann to its board.

NeoStem Inc., of New York, appointed Roberto Bolli to its scientific advisory board.

NexMed Inc., of San Diego, appointed Deirdre Y. Gillespie to its board.

NormOxys Inc., of Wellesley, Mass., appointed John A. Hey senior vice president of preclinical and early development.

Novavax Inc., of Rockville, Md., appointed John W. Madsen head of process and manufacturing operations and named Steven Pincus head of analytical and quality operations.

OpGen Inc., of Gaithersburg, Md., appointed C. Douglas White CEO.

OXIS International Inc., of Beverly Hills, Calif., appointed Okezie Aruoma president of its scientific advisory board, and Thomas W. Hoog was named to the board.

Par Pharmaceuticals Cos. Inc., of Woodcliff Lake, N.J., named Michael A. Tropiano executive vice president and chief financial officer.

PharmaGap Inc., of Ottawa, Ontario, appointed Ian Malone to its board.

Phytomedics Inc., of Jamesburg, N.J., appointed Jacques-Pierre Moreau to its board.

Pieris AG, of Freising-Weihenstephan, Germany, named Laurent Audoly chief scientific officer.

PolyTherics Ltd., of London, appointed Ken Cunningham chairman.

Pozen Inc., of Chapel Hill, N.C., elected Neal F. Fowler to its board.

Presidio Pharmaceuticals Inc., of San Francisco, added Pamela Vig as senior director of clinical research.

Probiodrug AG, of Halle, Germany, appointed Claus Braestrup chairman and named Lennart Mucke to its scientific advisory board.

Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., appointed Peter Crowley chairman.

Pro-Pharmaceuticals Inc., of Newton, Mass., named Peter G. Traber acting chief medical officer.

Raptor Pharmaceutical Corp., of Novato, Calif., named Lawrence Steinman to its advisory board.

Relypsa Inc., of Santa Clara, Calif., appointed Claire Lockey vice president of regulatory affairs.

Rigel Pharmaceuticals Inc., of South San Francisco, promoted Raul R. Rodriguez to president, Dolly Vance to general counsel and executive vice president of corporate affairs and Ryan Maynard to executive vice president and chief financial officer.

Sirius Genomics, of Vancouver, British Columbia, appointed Kamran Alam senior director of business development.

Spectrum Pharmaceuticals Inc., of Irvine, Calif., appointed James E. Shields senior vice president and chief commercial officer.

Spencer Pharmaceutical Inc., of Boston, named Max Arella president and chairman.

StemCells Inc., of Palo Alto, Calif., appointed R. Scott Greer to its board.

Talecris Biotherapeutics Holdings Corp., of Research Triangle Park, N.C., promoted John R. Perkins to executive vice president, global commercial operations.

TheraQuest Biosciences Inc., of Blue Bell, Pa., appointed Danny Kao senior vice president of pharmaceutical development and general counsel, and named Douglas R. Baum senior vice president of business development.

Vanda Pharmaceuticals Inc., of Rockville, Md., added Steven Galson to its board.

Vantia Therapeutics, of Southampton, UK, appointed Andrew Crockett CEO.

Xytos, of Carson City, Nev., appointed Farouk Dakhil chief scientific officer.

YM BioSciences Inc., of Mississauga, Ontario, appointed Nick Glover president and chief operating officer.